Lurbinectedin is a medication that has been approved by the US Food and Drug Administration (FDA) for the treatment of metastatic small cell lung cancer (SCLC) in patients who have received prior treatment with chemotherapy. Lurbinectedin is a synthetic analog of trabectedin, which is a chemotherapy agent that is used to treat soft tissue sarcoma. Lurbinectedin works by binding to the DNA molecule in cancer cells, which leads to the formation of a complex that prevents the cell from dividing and eventually causes the cell to die [2].

The FDA approval of lurbinectedin was based on the results of a clinical trial that involved 105 patients with metastatic SCLC who had received prior treatment with chemotherapy. The trial showed that treatment with lurbinectedin resulted in a response rate of 35%, with a median duration of response of 5.3 months. The most common side effects of lurbinectedin include fatigue, nausea, decreased appetite, musculoskeletal pain, and dyspnea [2].

Lurbinectedin is marketed under the brand name Zepzelca by PharmaMar, a Spanish pharmaceutical company. Zepzelca is available as a solution for intravenous infusion and is administered by a healthcare professional [1].

In conclusion, lurbinectedin is indicated for the treatment of metastatic small cell lung cancer in patients who have received prior treatment with chemotherapy. It works by binding to the DNA molecule in cancer cells and preventing the cell from dividing. Lurbinectedin is marketed under the brand name Zepzelca and is administered by a healthcare professional [1][2][3].

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf
[3] https://reference.medscape.com/drug/zepzelca-lurbinectedin-4000075